Biotech · Private company
SOTIO Biotech AG
Track this companyFree. Adds SOTIO Biotech AG to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- CAR-GPC3 T CellsPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Nanrilkefusp AlfaPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Nanrilkefusp alfaPhase 1 · Thyroid CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Thyroid CancerClinicalTrials.gov · fetched Nov 12, 2026
- SOT201Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic CancerPHASE1 · ACTIVE_NOT_RECRUITING · started May 1, 2024ClinicalTrials.gov NCT06163391 · fetched Nov 12, 2026
- BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 26, 2022ClinicalTrials.gov NCT05120271 · fetched Nov 12, 2026
- A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsPHASE2 · TERMINATED · started Jun 21, 2022ClinicalTrials.gov NCT05256381 · fetched Nov 12, 2026
- Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsPHASE1 · TERMINATED · started Jun 13, 2019ClinicalTrials.gov NCT04234113 · fetched Nov 12, 2026